Revelation Biosciences, Inc. Common Stock
Veridion Score
Composite trend over time
Why is REVB moving today?
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for REVB.
REVB insider activity
Revelation Biosciences, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net buying: $1.6M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | 2026-04-30 | Zygmont Chester Stanley III | Insider | sell | $1.10 | 13,285 | 92,063 | $15K | SEC Form 4 |
| 2026-05-01 | 2026-04-30 | Rolke James | Insider | sell | $1.13 | 10,115 | 214,738 | $11K | SEC Form 4 |
| 2026-02-05 | 2026-02-04 | Zygmont Chester Stanley III | Insider | sell | $1.65 | 13,100 | 105,348 | $22K | SEC Form 4 |
| 2026-02-05 | 2026-02-03 | Rolke James | Insider | sell | $1.86 | 8,521 | 224,853 | $16K | SEC Form 4 |
| 2026-02-05 | 2026-02-03 | CARVER JENNIFER | Insider | sell | $1.87 | 1,661 | 12,758 | $3K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 12 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moREVB contract awards, year to date.
Public federal awards linked to this ticker.
REVB lobbying filings, year to date.
Registered lobbying filings matched to Revelation Biosciences, Inc. Common Stock.